1. Castro MR and Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 142:926-931, 2005
2. Ezzat S, Sarti DA, Cain DR, et al. Thyroid incidentalomas prevalence by palpation and ultrasonography. Arch Intern Med 154:1838-1840, 1994
3. Dean DS and Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab 22:901-911, 2008
4. Gupta KL. Neoplasm of the thyroid gland. Clin Geriatr Med 11:271-290, 1995
5. Mazzaferri E Management of a solitary thyroid nodule. NEJM 328:553-559, 1993
6. Cavaliere R, Antonangeli L, Vitti P et al. The aging thyroid in a mild to moderate iodine deficient area of Italy. J Endocrinol Invest. 25:66-68, 2002
7. Diez JL. Goiter in adult patients aged 55 years and older: Etiology and clinical features in 634 Patients. J Gerontol A Biol Sci Med Sci 60:920-923, 2005
8. Plummer HS. The clinical and pathologic relationship of hyperplastic and nonhyperplastic goiters. JAMA 61:650, 1913
9. Hundahl SA, Fleming ID, Fremgen AM, et al. A national data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648, 1998
10. Davies L and Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167, 2006
11. Lin J, Chao T, Huang B, et al. Thyroid cancer in the thyroid nodules evaluated by ultrasonagraphy and fine-needle aspiration cytology. Thyroid 15:708-717, 2005
12. Lin JD, Chao TC, Chen ST, et al. Characteristics of thyroid carcinomas in aging patients. Eur J Clin Invest 30:147-153, 2000
13. Lerch H, Schober O, Kuwert T, et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Onc 15:2067-2075, 1997
14. Halnan KE. Influence of age and sex on incidence and prognosis of thyroid cancer. Cancer 19:1534-1536,: 1966
15. Sautter-Bihl M, Raub J, Hetzel-Sesterheim M, Heinze HG. Differentiated thyroid cancer. Prognostic factors and influence of treatment on the outcome in 441 patients. Strahlenther Onkol 177:125-131, 2000
16. Cady B, Sedgwick CE, Meissner WA, et al. Risk factor analysis in differentiated thyroid cancer. Cancer 43:810-820, 1979
17. Orlov S, Orlov D, Shaytzag M, et al. Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck. 2009 Mar 3. [Epub ahead of print]
18. Habra M, Sarlis NJ. Thyroid and aging. End & Met Dis 6:145-154, 2005
19. Bondeson L and Ljungbert O. Occult papillary thyroid carcinoma in the young and the aged. Cancer 53:1790-1792, 1984
20. Smith SA, Hay, ID, Goellner JR, et al. Mortality from papillary thyroid carcinoma. A case-control study of 56 lethal cases. Cancer 62:1381-1388, 1988
21. Tollefsen HR, DeCosse JJ, Hutter RVP. Papillary carcinoma of the thyroid: A clinical and pathological study of 70 fatal cases. Cancer 17:1035-1044, 1964
22. Woolner LB, Beahrs OH, Black BM, et al. Classification and prognosis of thyroid carcinoma. Am J Surg 102:354-387, 1961
23. Sampson RJ, Key CR, Buncher CR, et al. Thyroid carcinoma in hiroshima and nagasaki. JAMA 209:65-70, 1969
24. Brennan MD, Bergstralh, EJ, Van Heerden JA, et al. Follicular thyroid cancer treated at the mayo clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 66:11-22, 1991
25. Ladurner D, Zechmann W, Hofstadter F. Prognosis of the follicular thyroid carcinoma in an endemic goiter area-results of a retrospective study. Acta Endocrinol Suppl 252:28-29, 1983
26. Crile G, Pontius KI, Hawk WA. Factors influencing the survival of patients with follicular carcinoma of the thyroid gland. Surg Gynecol Obstet 160:409-413, 1985
27.Kebebew E, Ituarte PHG, Siperstein AE, et al. Medullary thyroid carcinoma clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139-1147, 2000
28. Saad MF, Ordonez NG, Rashid RK et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63:319, 1984
29. Scopsi L, Sampietro G, Boracchi P, et al. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 78:2173-2183, 1996
30. Aldinger KA, Samaan NA, Ibanez M, et al. Anaplastic carcinoma of the thyroid a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 41:2267-2275, 1978
31. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma treatment outcome and prognostic factors. Cancer 103:1330-1335, 2005
32. Veness MJ, Porter GS, Morgan GJ. Anaplastic thyroid carcinoma: Dismal outcome despite current treatment approach. ANZ J Surg 74:559-562, 2004
33. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. Cancer 89:202-217, 2000
34. Rizvi AA. Primary thyroid lymphoma review of clinical features and diagnostic evaluation. The Endocrinologist 14:144-147, 2004
35. Matsuzuka F, Miyauchi A, Katayama S, et al. Clinical aspects of primary thyroid lymphoma. Diagnosis and treatment based on our experience of 119 cases. Thyroid 3:93-99, 1993
36. Belal AA, Allam A, Kandil A, et al. Primary thyroid lymphoma: A retrospective analysis of prognostic factors and treatment outcome for localized intermediate and high grade lymphoma. Am J Clin Oncol 24:299-305, 2001
37. Derringer GA, Thompson LD, Frommelt RA, et al. Malignant lymphoma of the thyroid gland: A clinicopathologic study of 108 cases. Am J Surg Pathol 24:623639, 2000
38. Woolner LB, McConahey WM, Beahrs OH, et al. Primary malignant lymphoma of the thyroid. Am J Surg 111:502-523, 1966
39. Pyke CM, Grant CS, Habermann TM, et al. Primary non-hodgkin’s lymphoma of the thyroid. Eur J Surg Oncol 18:313-321, 1992
40. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Seimin Oncol 26:316-323, 1999
41. Uruno T, Miyauchi A, Shimizu K, et al. Favorable surgical results in 433 elderly patients with papillary thyroid cancer. World J Surg 29:1497-501, 2005
42. Ito Y, Tomoda C, Uruno T, et al. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg. 28:1115-21, 2004
43. Cooper DS, Doherty GM, Haugen BR, et al. Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 16: 1-33, 2006
44. Soroushyari A, Do D, Langton J, et al. Partial withdrawal of levothyroxine to stimulate serum thyroglobulin for thyroid cancer monitoring. Thyroid 14:1105-7, 2004
45. Dulgeroff AJ, Hershman JM. Medical Therapy for Differentiated Thyroid Carcinoma. Endocrine Reviews 15:500-515, 1994
46. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 82(2):375-88, 1998
47. Schwartz DL, Lobo ML, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomess and morbidity with conformal treatment. Internat J Radiation Oncology Biol Phys 75:1-9, 2009
48. Sawin CT, Geller A, Wolf AJB et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. NEJM 331:1249-1252, 1994
49. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. AHJ 142:838-842, 2001
50. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295:1033-1041, 2006
51. Faber J, Galloe AM Changes in bone mass during prolonged subclinical Hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130:350-356, 1994
52. Reverter JL, Holgado S, Alonso N, et al. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocrine-related cancer 12:973-981, 2005
53. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 81:4278-89, 1996
54. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the national thyroid cancer treatment cooperative registry. Thyroid 8:737-744, 1998
55. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive Differentiated thyroid cancer. NEJM 359:31-42, 2008
56. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II Trial of Sorafenib in advanced thyroid cancer. J of Clin Onc 26:4714-4719, 2008